Posting of Annual Report & Notice of Annual General Meeting
Hemogenyx Pharmaceuticals plc
(“Hemogenyx Pharmaceuticals” or the “Company”)
LEI 2138008L93GYU5GN6179
Posting of Annual Report & Notice of Annual General Meeting
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group, confirms that the Annual Report and Accounts for the year ended 31 December 2021, the Notice of the Annual General Meeting (“AGM”) and a Form of Proxy were posted to shareholders today and are available on the Company’s website at https://hemogenyx.com/investors/annual-and-half-year-reports, and the 2021 Equity Incentive Plan with Non-Employee Sub-Plan (relating to AGM Resolution 5) is available on the Company’s website at https://hemogenyx.com/investors/company-profile/company-information.
The AGM is to be held on 30 June 2022 at 2.00 pm BST at the offices Shakespeare Martineau LLP, 60 Gracechurch Street, London EC3V 0HR.
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
| Peter Redmond, Director | peter.redmond@hemogenyx.com |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |